(Reuters) -Sanofi plans to seek U.S. approval for its best-selling anti-inflammatory drug Dupixent to be used in the treatment of "smoker's lung", also known as COPD, after a second large trial showed ...

Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter The RAPID registry from Regeneron and Sanofi tracks how real patients with asthma start ...

A diagnosis of T-cell lymphoma after using Dupixent raises serious questions for patients and families. Many want clear answers about whether they may have a legal claim and what criteria determine ...

If you or a loved one was diagnosed with cutaneous T-cell lymphoma (CTCL) while taking Dupixent, you may be wondering whether ...

Dupixent single-dose prefilled pens feature a hidden needle and single-press auto-injection. The Food and Drug Administration (FDA) has expanded the approval of the Dupixent ® (dupilumab) single-dose ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

TARRYTOWN, N.Y. and PARIS, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency’s Committee for Medicinal ...

Dupixent showed significant and clinically meaningful improvements in both esophageal distensibility as well as disease-related structural changes and inflammation in the esophagus in adult patients ...

Please provide your email address to receive an email when new articles are posted on . The FDA has expanded approval of the single-dose Dupixent pre-filled pen for use in children aged as young as 2 ...

Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study Study met the primary and all key secondary ...